The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Institution: LMU Munich ICML 2023 | Association of host hematopoiesis with CAR-T hematotoxicity and efficacy in LBCL
Kai Rejeski, MD, LMU Munich, Munich, Germany, shares the findings of an observational study which aimed to understand the underlying pathophysiology of CAR-T-related hematologic toxicities in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). In this study, patients who received CAR-T therapy were stratified by the phenotype of neutrophil recovery into three groups: quick, intermittent, and aplastic. Patients with the aplastic phenotype experienced high non-relapse mortality and prolonged hospitalization, while those with the intermittent phenotype had improved outcomes compared to the other two groups. Dr Rejeski shares the data on CAR-T dynamics for all groups, which highlighted interactions between host hematopoiesis and CAR-T efficacy and persistence. These results suggest that neutrophil recovery phenotypes could be integrated into risk models of treatment outcomes, though further research is required to understand the underlying mechanisms. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
